Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy. (MARTA)

  • End date
    Dec 20, 2025
  • participants needed
  • sponsor
    Institut Claudius Regaud
Updated on 20 April 2022


Prospective, multicentric, non-randomized phase II study evaluating the surgical treatment by mastectomy with immediate prosthetic breast reconstruction in patients with breast cancer and receiving adjuvant therapy by TomoTherapy +/-Chemotherapy.

Patients with non-inflammatory and non-metastatic invasive mammary carcinoma will be included in this study.

The study procedure will be a surgical treatment by mastectomy with immediate prosthetic breast reconstruction followed by an adjuvant therapy: TomoTherapy +/-Chemotherapy (radiation therapy alone or preceded by chemotherapy).

The nature of the chemotherapy treatment will be decided according to the standards of each center.

The patients will be followed for the study up to 36 months after the surgical procedure.

Condition Breast Cancer Invasive
Treatment Patients with invasive breast cancer will receive:
Clinical Study IdentifierNCT03627988
SponsorInstitut Claudius Regaud
Last Modified on20 April 2022


Yes No Not Sure

Inclusion Criteria

Age ≥ 18 years
Patient with a non-inflammatory and non-metastatic invasive mammary carcinoma
Indication of mastectomy and immediate prosthetic breast reconstruction
Patient wishing to have an immediate mammary reconstruction with prosthesis
Formal or presumptive pre-operative indication for adjuvant radiotherapy (+/- chemotherapy)
OMS ≤ 2
Patient affiliated to a Social Health Insurance in France
Patient must provide written informed consent prior to any study specific procedures

Exclusion Criteria

Metastatic breast cancer
Bilateral breast cancer
Inflammatory breast cancer (T4d)
History of breast cancer within 5 years
Not applicable according to the protocol version N°6 : Previous neoadjuvant treatment for the ongoing disease
Pregnant or breastfeeding women
Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure
Patient protected by law
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note